Higher CCDC69 expression in the responder groups and lower CCDC69 expression in the non-responder groups after ICI treatments were observed in the breast cancer model (T11, p53-2225 L) (Fig. 12B, C), melanoma model (B16, YUMM1.7) (Fig. 12D, E), and lung cancer model (LCC) in vivo (Fig. 12F). This evidence concerns the gene TP53 and lung carcinoma.